Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1414TiP - Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

D. Ross Camidge

Citation

Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283

Authors

D..R. Camidge1, J.W. Goldman2, G.W. Cole3, Z. Sun4, C.J. Ocampo3, P. Komarnitsky3, V. Blot3

Author affiliations

  • 1 Medical Oncology, University of Colorado Cancer Center, 80045 - Aurora/US
  • 2 David Geffen School Of Medicine, UCLA, Los Angeles/US
  • 3 Oncology Clinical Development, AbbVie Inc., 60064 - North Chicago/US
  • 4 Data And Statistical Sciences, AbbVie Inc., 60064 - North Chicago/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1414TiP

Background

Acquired resistance to third-generation epidermal growth factor receptor (EGFR) inhibitors (eg, osimertinib) may result in MET gene amplification and/or c-MET protein overexpression. Telisotuzumab vedotin (ABBV-399; teliso-v), an anti–c-MET antibody-drug conjugate that can both disrupt c-MET signaling and deliver a cytotoxic payload into tumor cells, has shown antitumor activity in a phase 1/1b trial (NCT02099058) in patients (pts) with non-small cell lung cancer (NSCLC) with c-MET overexpression. Here we describe the teliso-v plus osimertinib cohort (arm E) of this trial.

Trial design

Arm E of this phase 1/1b open-label study evaluates safety, pharmacokinetics, and preliminary efficacy of teliso-v, administered intravenously once every 2 weeks, in combination with oral osimertinib (80 mg once a day) in pts with metastatic NSCLC whose disease progressed on osimertinib. Pts must have documented osimertinib-sensitive EGFR mutations, and c-MET overexpression (defined by central immunohistochemistry test) in tumor tissue obtained post-osimertinib progression. Arm E consists of safety lead-in (SLP; n=3–6), safety evaluation (SEP; n=3–12), and expansion (n=3–12) phases. Teliso-v will first be evaluated at 1.6 mg/kg and escalated to 1.9 mg/kg on the basis of safety signals in SLP and SEP phases. Radiographic tumor assessments will continue until disease progression, start of a new anticancer therapy, death, or consent withdrawal. Response evaluation will be based on Response Evaluation Criteria in Solid Tumors version 1.1. Planned enrollment is 3–24 pts; to date, 3 pts are enrolled.

Clinical trial identification

NCT02099058.

Editorial acknowledgement

Medical writing support was provided by Mary L. Smith, PhD, CMPP, from Aptitude Health, Atlanta, GA, and funded by AbbVie.

Legal entity responsible for the study

AbbVie.

Funding

AbbVie Inc.

Disclosure

D.R. Camidge: Advisory/Consultancy, Research grant/Funding (institution): AbbVie. J.W. Goldman: Research grant/Funding (institution): AbbVie; Honoraria (self), Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Genentech/Roche.

G.W. Cole, Z. Sun, C.J. Ocampo, P. Komarnitsky, V. Blot: Shareholder/Stockholder/Stock options, Full/Part-time employment: AbbVie.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.